Median ALS survival extended 44%, to 25.0 months, by experimental drug

Reuters Health - 16/10/2020 - Additional results from the phase 2 CENTAUR study on patients with amyotrophic lateral sclerosis (ALS) show that the experimental Amylyx Pharmaceuticals drug AMX0035 increases survival by 44% compared to conventional therapy. Median overall survival was 18.5 months in the standard care group versus 25.0 months with the test treatment, a combination of sodium phenylbutyrate and taurursodiol (aka tauroursodeoxycholic acid) (P=0.023). The oral drug is also known as PB-TURSO. People diagnosed with ALS typically die within 2 or 3 years, usually from respiratory failure. The results are published in the journal Muscle & Nerve. The Amylyx-financed trial was done at 25 centers in the U.S. Earlier results published last month by the New England Journal of Medicine showed that the drug could significantly, although not dramatically, slow the progression of the fatal illness, at least by one measure. The new report directl...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 16 October, 202022 October, 2020